162,313 Shares in Caris Life Sciences, Inc. $CAI Acquired by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas bought a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 162,313 shares of the company’s stock, valued at approximately $4,379,000. Oddo BHF Asset Management Sas owned about 0.06% of Caris Life Sciences at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CAI. Global Retirement Partners LLC lifted its position in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC bought a new stake in Caris Life Sciences in the fourth quarter valued at approximately $31,000. MetLife Investment Management LLC lifted its position in Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the last quarter. Federated Hermes Inc. bought a new stake in Caris Life Sciences in the fourth quarter valued at approximately $81,000. Finally, Adams Street Partners LLC bought a new stake in Caris Life Sciences in the fourth quarter valued at approximately $132,000.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Jefferies Financial Group initiated coverage on Caris Life Sciences in a research report on Monday, April 13th. They issued a “buy” rating and a $28.00 price objective for the company. Weiss Ratings raised Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Canaccord Genuity Group reduced their target price on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. Wolfe Research cut Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $27.56.

Caris Life Sciences Stock Down 1.1%

NASDAQ CAI opened at $17.98 on Wednesday. The stock has a 50-day moving average of $17.74. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.05 and a quick ratio of 6.52. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The company has a market capitalization of $5.08 billion and a P/E ratio of -2.36.

Caris Life Sciences declared that its board has authorized a stock repurchase plan on Monday, June 8th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to buy up to 2.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Caris Life Sciences news, Director Jeff L. Vacirca bought 31,050 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the transaction, the director owned 49,671 shares of the company’s stock, valued at $802,186.65. This trade represents a 166.75% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 50.00% of the company’s stock.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.